PT817650E - Peptidos sinteticos e composicoes farmaceuticas que os contem para o tratamento do lupus eritematoso sistemico - Google Patents
Peptidos sinteticos e composicoes farmaceuticas que os contem para o tratamento do lupus eritematoso sistemicoInfo
- Publication number
- PT817650E PT817650E PT96911449T PT96911449T PT817650E PT 817650 E PT817650 E PT 817650E PT 96911449 T PT96911449 T PT 96911449T PT 96911449 T PT96911449 T PT 96911449T PT 817650 E PT817650 E PT 817650E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- pharmaceutical compositions
- synthetic peptides
- systemic
- eritematosus
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 230000003172 anti-dna Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11315995A IL113159A0 (en) | 1995-03-28 | 1995-03-28 | Synthetic peptides and pharmaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT817650E true PT817650E (pt) | 2004-03-31 |
Family
ID=11067281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96911449T PT817650E (pt) | 1995-03-28 | 1996-03-27 | Peptidos sinteticos e composicoes farmaceuticas que os contem para o tratamento do lupus eritematoso sistemico |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0817650B1 (pt) |
| JP (1) | JP3862752B2 (pt) |
| AT (1) | ATE253944T1 (pt) |
| AU (1) | AU706772B2 (pt) |
| CA (1) | CA2217776C (pt) |
| DE (1) | DE69630682T2 (pt) |
| DK (1) | DK0817650T3 (pt) |
| ES (1) | ES2212801T3 (pt) |
| IL (2) | IL113159A0 (pt) |
| PT (1) | PT817650E (pt) |
| WO (1) | WO1996030057A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613536B1 (en) * | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK1783222T3 (da) | 1998-10-23 | 2012-07-09 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| EP1511772B1 (en) * | 2002-05-28 | 2011-11-23 | Omrix Biopharmaceuticals Inc. | Method for obtaining anti-idiotype antibodies |
| CA2513331A1 (en) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| JP4817068B2 (ja) * | 2003-01-14 | 2011-11-16 | イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド | 全身性エリテマトーデスの治療のためのペプチドの非経口製剤 |
| JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69230612T2 (de) * | 1991-05-31 | 2000-06-21 | Connetics Corp., Palo Alto | T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten |
-
1995
- 1995-03-28 IL IL11315995A patent/IL113159A0/xx unknown
-
1996
- 1996-03-27 AU AU54334/96A patent/AU706772B2/en not_active Ceased
- 1996-03-27 JP JP52962296A patent/JP3862752B2/ja not_active Expired - Fee Related
- 1996-03-27 DK DK96911449T patent/DK0817650T3/da active
- 1996-03-27 ES ES96911449T patent/ES2212801T3/es not_active Expired - Lifetime
- 1996-03-27 WO PCT/US1996/004206 patent/WO1996030057A1/en not_active Ceased
- 1996-03-27 AT AT96911449T patent/ATE253944T1/de not_active IP Right Cessation
- 1996-03-27 IL IL11768696A patent/IL117686A/xx not_active IP Right Cessation
- 1996-03-27 EP EP96911449A patent/EP0817650B1/en not_active Expired - Lifetime
- 1996-03-27 PT PT96911449T patent/PT817650E/pt unknown
- 1996-03-27 DE DE69630682T patent/DE69630682T2/de not_active Expired - Lifetime
- 1996-03-27 CA CA002217776A patent/CA2217776C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK0817650T3 (da) | 2004-03-08 |
| IL117686A0 (en) | 1996-07-23 |
| AU5433496A (en) | 1996-10-16 |
| ES2212801T3 (es) | 2004-08-01 |
| DE69630682D1 (de) | 2003-12-18 |
| EP0817650A1 (en) | 1998-01-14 |
| IL117686A (en) | 2000-10-31 |
| EP0817650A4 (en) | 1999-09-01 |
| CA2217776A1 (en) | 1996-10-03 |
| DE69630682T2 (de) | 2004-09-16 |
| AU706772B2 (en) | 1999-06-24 |
| EP0817650B1 (en) | 2003-11-12 |
| CA2217776C (en) | 2004-12-07 |
| IL113159A0 (en) | 1995-06-29 |
| JPH11503124A (ja) | 1999-03-23 |
| ATE253944T1 (de) | 2003-11-15 |
| WO1996030057A1 (en) | 1996-10-03 |
| JP3862752B2 (ja) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT817650E (pt) | Peptidos sinteticos e composicoes farmaceuticas que os contem para o tratamento do lupus eritematoso sistemico | |
| CY1107708T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης | |
| MX9603080A (es) | Anticuerpos monoclonales inmuno-estimulantes. | |
| MX169992B (es) | Conjugados de estrella explotada | |
| PT941121E (pt) | Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais | |
| ES2173130T3 (es) | Metodo de fijacion de material al peptido beta-amiloide. | |
| AR021296A1 (es) | Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden | |
| NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
| TNSN93012A1 (fr) | Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine | |
| EA199900621A1 (ru) | Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1 | |
| DK0845998T3 (da) | Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles | |
| ES2116789T3 (es) | Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo. | |
| DK0720624T3 (da) | Omdirigering af antistoffer | |
| ES2141086T3 (es) | Anticuerpos contra los ligando-analogos y su uso en los dosificados ligando-receptores. | |
| NO884368D0 (no) | Immunobestemmelse under anvendelse av iggoppfangningsantigen, og multippel antistoffpaavisningssystem. | |
| MX24890A (es) | Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene. | |
| ES2127531T3 (es) | Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales. | |
| PE20010046A1 (es) | Anticuerpos anti-idiotipicos recombinantes | |
| EP0770624A3 (en) | Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer | |
| ES2149159T3 (es) | Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion. | |
| ES2117272T3 (es) | Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas. | |
| WO2000001729A3 (en) | Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome | |
| BR0114977A (pt) | segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos | |
| FR2694938B1 (fr) | Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant. | |
| PT951481E (pt) | Utilizacao de substancias com accao imunomoduladora para o tratamento da esclerose lateral amiotrofica |